TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36544211

Group type: EXPERIMENTAL
Intervention: Daily intake of soybeans and flaxseeds (~ 200 mg of phytoestrogens) until surgery (approximately 6 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 200
Study: 36544226

Group type: EXPERIMENTAL
Intervention: Score-based model for predicting severe vitamin D deficiency (SVDD)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: SVDD score based on multivariable logistic regression (MLR) model
Number of subjects: 662
Study: 36544398

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (DVI)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: No oxytocin for labor progression
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Oxytocin for induction
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Oxytocin for augmentation
Number of subjects: 1107
Study: 36544548

Group type: EXPERIMENTAL
Intervention: Frondanol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36544965

Group type: EXPERIMENTAL
Intervention: POSTi NLR values in infected group aged 0-4 years
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: POSTi NLR values in infected group aged over 18 years
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Preoperative NLR and PLR values
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NLR values at first admission to the hospital
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (29 patients without CI infection)
Number of subjects: 26
Study: 36545256

Group type: EXPERIMENTAL
Intervention: Thiopurine 6-thioguanine (6TG) treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study: 36545312

Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment in patients with CYP3A4*22 and CYP3A5 genotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36545322

Group type: EXPERIMENTAL
Intervention: Ceritinib and Trametinib
Number of subjects: 9
Study: 36546322

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 577

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 577
Study: 36546346

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 2636
Study: 36546351

Group type: EXPERIMENTAL
Intervention: Goal-Setting group (received health vouchers for meeting sleep goals)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study: 36546402

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 3038

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 3038
Study: 36546422

Group type: EXPERIMENTAL
Intervention: Clarithromycin and lenalidomide, specific dosages and duration not available
Number of subjects: 0
Study: 36546453

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Real-world clinical practice (RWCP)
Number of subjects: 113
Study: 36546479

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (4 μg/kg initial dose, followed by 2 μg/kg if needed)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 1091
Study: 36546511

Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention in schools
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention
Number of subjects: 1890
Study: 36546588

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36546623

Group type: EXPERIMENTAL
Intervention: Cumulative average VAI in quartiles (3-4 quartiles ≥2.6)
Number of subjects: 10132

Group type: COMPARATOR
Intervention: Cumulative average VAI in quartiles (1-2 quartiles <2.6)
Number of subjects: 10132

Group type: EXPERIMENTAL
Intervention: Cumulative average systolic blood pressure <130 mmHg
Number of subjects: 10132
Study: 36546624

Group type: EXPERIMENTAL
Intervention: Weekly dupilumab (300 mg)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks (300 mg)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 239
Study: 36546626

Group type: EXPERIMENTAL
Intervention: Lentiviral gene-corrected autologous CD34+ cells infusion
Number of subjects: 10
Study: 36546625

Group type: EXPERIMENTAL
Intervention: BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) for 24 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard-care regimen for 9-to-20 months
Number of subjects: 301
Study: 36546651

Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 38
Study: 36546659

Group type: EXPERIMENTAL
Intervention: Adagrasib monotherapy (600 mg orally twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Adagrasib in combination with cetuximab (initial loading dose of 400 mg/m², followed by 250 mg/m² weekly or 500 mg/m² every 2 weeks)
Number of subjects: 76
Study: 36547147

Group type: EXPERIMENTAL
Intervention: Linac-based SBRT on the prostate bed, total dose of 32.5 Gy in five fractions every other day.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Linac-based SBRT on the prostate bed
Number of subjects: 30
Study: 36547262

Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block (QLB) with 3.75 mg/ml ropivacaine 20 ml/side
Number of subjects: 39

Group type: COMPARATOR
Intervention: Epidural analgesia with ropivacaine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block (QLB)
Number of subjects: 39
Study: 36547975

Group type: EXPERIMENTAL
Intervention: Oral β-glucan during the first 5 weeks of vaccine priming (group 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: GD2/GD3 vaccine without β-glucan (group 1)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral β-glucan during vaccine boost (both groups)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Anti-GD2 IgG1 titer of 230 ng/mL or greater by week 8
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Correlation of antibody titer with dectin-1 SNP
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Seroconversion rates
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Vaccine-related toxic effects
Number of subjects: 107
Study: 36548028

Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 46
Study: 36548042

Group type: EXPERIMENTAL
Intervention: Children's social information processing (SIP)
Number of subjects: 0
Study: 36548078

Group type: EXPERIMENTAL
Intervention: Experimental condition blocking the devaluation of medical reassurance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (depressed and healthy people)
Number of subjects: 0
Study: 36548143

Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG) and health education during eight ANC visits
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care consisting of four ANC visits and two USG
Number of subjects: 288
Study: 36548225

Group type: EXPERIMENTAL
Intervention: 7-day course of any active antibiotic
Number of subjects: 304

Group type: COMPARATOR
Intervention: 14-day course of any active antibiotic
Number of subjects: 304
Study: 36548281

Group type: EXPERIMENTAL
Intervention: Home-based screening test for albuminuria using a conventional urine collection device
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Home-based screening test for albuminuria using an innovative smartphone application
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Central screening facility for elaborate screening for CKD and CVD risk factors (following positive home test)
Number of subjects: 15000
Study: 36548338

Group type: EXPERIMENTAL
Intervention: Structured Aerobic Exercise Protocol (SAEP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual Care Exercise Prescription (UCEP)
Number of subjects: 38
Study: 36548444

Group type: COMPARATOR
Intervention: Standard treatment (single dose of praziquantel)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intense treatment (4 repeated doses of praziquantel at 2-week intervals)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 125
Study: 36548448

Group type: EXPERIMENTAL
Intervention: Nudge intervention (ChooseWell 365)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 487
Study: 36548543

Group type: EXPERIMENTAL
Intervention: Longitudinal Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study: 36548927

Group type: EXPERIMENTAL
Intervention: Subcutaneous epcoritamab
Number of subjects: 157
Study: 36549084

Group type: EXPERIMENTAL
Intervention: Severe OSA patients with recurrent cardiovascular events (CVE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Severe OSA patients without recurrent cardiovascular events (CVE)
Number of subjects: 86
Study: 36549090

Group type: EXPERIMENTAL
Intervention: Pupillometry parameters (baseline pupillary diameter, PD; PD variations, PDV; pupillary constriction velocity, PCV)
Number of subjects: 50
Study: 36549308

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg per kg of bodyweight, maximum 25 mg)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control (no thrombolysis)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control
Number of subjects: 578
Study: 36549320

Group type: EXPERIMENTAL
Intervention: Levofloxacin-based sequential quadruple therapy for 14 days (EAML14); esomeprazole 40 mg and amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, metronidazole 500 mg, and levofloxacin 250 mg for 7 days, all twice-daily.
Number of subjects: 560

Group type: COMPARATOR
Intervention: Bismuth-based quadruple therapy for 10 days (BQ10); esomeprazole 40 mg twice daily, bismuth tripotassium dicitrate 300 mg four times a day, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day.
Number of subjects: 560

Group type: COMPARATOR
Intervention: Levofloxacin-based sequential quadruple therapy (EAML14) and Bismuth-based quadruple therapy (BQ10)
Number of subjects: 560
Study: 36549342

Group type: EXPERIMENTAL
Intervention: Approach Positive training (n=21)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Balanced training (n=24)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 36549347

Group type: EXPERIMENTAL
Intervention: Cetuximab with radiation and cisplatin (arm B)
Number of subjects: 891

Group type: COMPARATOR
Intervention: Radiation and cisplatin without cetuximab (arm A)
Number of subjects: 891
Study: 36549722

Group type: EXPERIMENTAL
Intervention: Early enrollers (DSD enrolment after <6 months on ART)
Number of subjects: 32197

Group type: COMPARATOR
Intervention: Established enrollers (DSD enrolment after ≥6 months on ART)
Number of subjects: 32197

Group type: EXPERIMENTAL
Intervention: Early enrollers
Number of subjects: 32197
Study: 36549723

Group type: EXPERIMENTAL
Intervention: Pharmacist-conducted medication reconciliation
Number of subjects: 0
Study: 36549727

Group type: EXPERIMENTAL
Intervention: Extended HPV genotyping (pool_1: HPV 16, 18, 45; pool_2: HPV 16, 18, 45, 31, 33, 35, 52, 58)
Number of subjects: 2014

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 2014

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 2014

Group type: EXPERIMENTAL
Intervention: Extended HPV genotyping
Number of subjects: 2014

Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 2014
Study: 36549740

Group type: EXPERIMENTAL
Intervention: Free access to a comprehensive list of essential medicines for 24 months
Number of subjects: 786
Study: 36549741

Group type: EXPERIMENTAL
Intervention: PLAYshop programme
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 36549747

Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 100
Study: 36549749

Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Active attention control (text message reminders)
Number of subjects: 400
Study: 36549781

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO+IPI)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 139
Study: 36549786

Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) for 12 weeks, training twice daily using a threshold inspiratory muscle trainer
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 26
Study: 36549898

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily, increased to 20 mg daily after 4 weeks if no toxicity
Number of subjects: 67
Study: 36550063

Group type: EXPERIMENTAL
Intervention: 16-min educational video on aneuploidy screening
Number of subjects: 286

Group type: COMPARATOR
Intervention: Routine counselling (Control)
Number of subjects: 286
Study: 36550396

Group type: EXPERIMENTAL
Intervention: Virtual dietary behavior intervention
Number of subjects: 0
Study: 36550417

Group type: EXPERIMENTAL
Intervention: Supermaximum recession resection (group S)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Augmented recession by lateral rectus muscle elongation with an autograft from the resected medial rectus muscle (group E)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both groups (S and E)
Number of subjects: 54
Study: 36550428

Group type: EXPERIMENTAL
Intervention: Two additional cycles of Lutathera® (7.4 GBq infusion each, separated by 8 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No treatment (active surveillance)
Number of subjects: 146
Study: 36550451

Group type: EXPERIMENTAL
Intervention: Smart Toothbrush and Smart Mirror (STM) system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional Tooth Brushing Instruction (TBI)
Number of subjects: 42
Study: 36550466

Group type: EXPERIMENTAL
Intervention: Refusal documentation method
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPV vaccine refusal
Number of subjects: 7
Study: 36550496

Group type: EXPERIMENTAL
Intervention: Telemedicine (TLM) programme assessments every 3 months
Number of subjects: 426

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Telemedicine (TLM) programme
Number of subjects: 426
Study: 36550559

Group type: EXPERIMENTAL
Intervention: 500 mL crystalloid fluid bolus (FB) administered over 30 min
Number of subjects: 130

Group type: COMPARATOR
Intervention: non-interventional follow-up (FU) for 2 hours
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 500 mL crystalloid fluid bolus (FB)
Number of subjects: 130

Group type: COMPARATOR
Intervention: non-interventional follow-up (FU)
Number of subjects: 130
Study: 36550562

Group type: EXPERIMENTAL
Intervention: Clazakizumab (12.5 mg subcutaneous once every 4 weeks)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 350
Study: 36550564

Group type: EXPERIMENTAL
Intervention: HIIT group (34 women)
Number of subjects: 54

Group type: COMPARATOR
Intervention: EDU group (20 women)
Number of subjects: 54
Study: 36550568

Group type: COMPARATOR
Intervention: Diastole-synchronized compressions/decompressions (DSCD) for 20 minutes in Study 1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diastole-synchronized compressions/decompressions (DSCD) for 60 minutes, three times/week for three months in Study 2
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control session (simulated) in Study 1
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control period (without simulated sessions) in Study 2
Number of subjects: 54
Study: 36550636

Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCE participants
Number of subjects: 0
Study: 36550683

Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and Irinotecan (120 mg/m2 days 1 and 8 every 3 weeks)
Number of subjects: 21
Study: 36551626

Group type: EXPERIMENTAL
Intervention: MRX-2843
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MRX-2843 with venetoclax
Number of subjects: 39
Study: 36551677

Group type: EXPERIMENTAL
Intervention: SAMITAL granules for oral suspension (20 mL, four times daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: SAMITAL granules for oral suspension
Number of subjects: 116
Study: 36551718

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 32
Study: 36552013

Group type: EXPERIMENTAL
Intervention: Study group (%VO2pred < 80%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (%VO2pred ≥ 80%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression model
Number of subjects: 120
Study: 36552120

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RTGT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Therapist-assisted treadmill gait training (TTGT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both RTGT and TTGT
Number of subjects: 120
Study: 36553294

Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Medical treatment for SDB
Number of subjects: 286

Group type: COMPARATOR
Intervention: No treatment for SDB
Number of subjects: 286
Study: 36553313

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (5 min audio recording focusing on breathing and nonjudgmental attention)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition (5 min audio recording involving an unfocused attention task)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study: 36554485

Group type: EXPERIMENTAL
Intervention: SAVE system (technology-based elderly care system)
Number of subjects: 165
Study: 36554543

Group type: EXPERIMENTAL
Intervention: Borg's rating of perceived exertion (BRPE) scale during treadmill walking
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Borg's rating of perceived exertion (BRPE) scale during outdoor uphill cardio-trekking test (1 km CTT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Sensor-based, objective exercise-intensity parameters such as heart rate (HR)
Number of subjects: 134
Study: 36554581

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety in paediatric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High level of preoperative anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average postoperative pain at rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients' age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental trait anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female gender of parents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous route for postoperative pain management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety in patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female gender of children
Number of subjects: 0
Study: 36554612

Group type: EXPERIMENTAL
Intervention: Adapted judo program (90 min practice each week for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study: 36554652

Group type: EXPERIMENTAL
Intervention: Cycling wheelchair training for 30 min a day, 5 days a week, for 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cycling wheelchair training
Number of subjects: 41
Study: 36554820

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic therapy with Johanna (good outcome)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic therapy with Sonja (poor outcome)
Number of subjects: 2
Study: 36554830

Group type: EXPERIMENTAL
Intervention: FrenChILD-Index for moderate deprivation
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: FrenChILD-Index for severe deprivation
Number of subjects: 986
Study: 36554860

Group type: EXPERIMENTAL
Intervention: Virtual Reality-based pulmonary rehabilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional form of therapy (Control)
Number of subjects: 32
Study: 36555879

Group type: EXPERIMENTAL
Intervention: Calf neuromuscular electrical stimulation (NMES) program for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 0
Study: 36555933

Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo→Rituximab 1000 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo→Rituximab 500 mg
Number of subjects: 83
Study: 36556365

Group type: EXPERIMENTAL
Intervention: Single-stage retrograde endoscopic stone removal during initial ERCP
Number of subjects: 123
Study: 36556977

Group type: EXPERIMENTAL
Intervention: Kerecis (Intact Fish Skin Graft)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study: 36557750

Group type: EXPERIMENTAL
Intervention: Oropharyngeal microbiota with inhibitory activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36560565

Group type: EXPERIMENTAL
Intervention: BC02 (BCG CpG DNA compound adjuvants system 02)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant Glycoprotein E of Varicella-Zoster Virus
Number of subjects: 0
Study: 36560966

Group type: EXPERIMENTAL
Intervention: Mitomycin C pressurized intraperitoneal aerosolized chemotherapy (MMC-PIPAC) combined with systemic chemotherapy (FOLFIRI)
Number of subjects: 0
Study: 36561174

Group type: EXPERIMENTAL
Intervention: Ivermectin 600 μg/kg daily for 6 days
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Placebo daily for 6 days
Number of subjects: 1206
Study: 36561483

Group type: EXPERIMENTAL
Intervention: Handheld ultrasound-guided dynamic needle position technique
Number of subjects: 118

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 118